The Food and Drug Administration is seeking to pull its approval of the drug Tavneos, according to Ars Technica. The regulator contends that the medication was originally approved on the basis of manipulated study data. The effort underscores how difficult it can be to reverse a drug approval once it has been granted. Patients currently using Tavneos may be left wondering whether they will continue to have access to the treatment. The situation raises a challenging question for health officials: should patients still be able to obtain a drug if its approval was tied to compromised data? Ars Technica reported that the process is far from simple, with regulatory and practical obstacles complicating the FDA's attempt to withdraw authorization.
Source: Ars Technica.
